2-甲基-哌啶-3-羧酸 | 116140-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 2-甲基-哌啶-3-羧酸
• 中文别名: 2-甲基-哌啶-3-甲酸
• 英文名称: acide methyl-2 nipecotique
• 英文别名: 2-Methylpiperidine-3-carboxylic acid
• CAS: 116140-14-8
• 化学式: C₇H₁₃NO₂
• 分子量: 143.186
• InChiKey: LAWPBIIDJCWFFN-UHFFFAOYSA-N

物化性质

• 沸点：
  267.0±33.0 °C(Predicted)
• 密度：
  1.062±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-甲基-哌啶-3-羧酸 在 sodium hydroxide 、 N-羟基-7-氮杂苯并三氮唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 (2R)-N-methyl-2-(N-methyl-N-((2R)-2-(N-methyl-N-((2-methylpiperidin-3-yl)carbonyl)amino)-3-(2-naphthyl)propionyl)amino)-3-phenylpropionamide
  参考文献：
  名称：

  Synthesis and in vitro characterization of new growth hormone secretagogues derived from ipamorelin with dipeptidomimetic N-terminals

  摘要：

  The structural requirements for N-terminal features for the minimal structure of growth hormone secretagogues derived from ipamorelin are investigated. It is found, that incorporation of nonpolar peptidomimetic amino acids at the N-terminal can replace the Aib-His moiety and lead to compounds with high in vitro potency with respect to their growth hormone secretagogue properties. New unnatural amino acids with double bonds, ether-linkages, and 1,3-phenylene-moieties in the backbone proved to be valuable dipeptidomimetics. Using them, growth hormone secretagogues with high potencies were obtained. (C) Elsevier, Paris.

  DOI：

  10.1016/s0223-5234(99)80086-5
• 作为产物：
  描述：

  methyl-2 nipecotate d'ethyle 以57%的产率得到
  参考文献：
  名称：

  LAPUYADE G.; SCHLEWER G.; WERMUTH C. -G., BULL. SOC. CHIM. FR.,(1986) N 7-8, 663-668

  摘要：

  DOI：

文献信息

• NITROGEN-CONTAINING SATURATED HETEROCYCLIC COMPOUND
  申请人：SUMITOMO CHEMICAL COMPANY, LIMITED

  公开号：US20160221948A1

  公开（公告）日：2016-08-04

  The present invention provides a compound represented by the following formula (I) or its pharmaceutically acceptable salt: [wherein, R 1 represents optionally substituted C 1-4 alkyl, n shows integer of 1 to 4, R 2 represents optionally substituted C 1-4 alkyl or hydrogen atom, R 3 represents optionally substituted C 1-4 alkyl, R 4a , R 4b , R 4c , and R 4d , similarly or differently, represent optionally substituted C 6-14 aryl, optionally substituted C 1-4 alkyl, or hydrogen atom and the like, A represents optionally substituted C 6-14 aryl or optionally substituted 5 to 11 membered heteroaryl].

  本发明提供了一种由下式(I)表示的化合物或其药用可接受的盐： [其中，R1表示可选地取代的C1-4烷基，n表示1到4的整数，R2表示可选地取代的C1-4烷基或氢原子，R3表示可选地取代的C1-4烷基，R4a、R4b、R4c和R4d，相同或不同，表示可选地取代的C6-14芳基，可选地取代的C1-4烷基，或氢原子等，A表示可选地取代的C6-14芳基或可选地取代的5至11成员的杂芳基]。
• [EN] 7-, 8-, and 10-SUBSTITUTED AMINO TRIAZOLO QUINAZOLINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS, PHARMACEUTICAL COMPOSITIONS AND THEIR USE<br/>[FR] DÉRIVÉS D'AMINO TRIAZOLO QUINAZOLINE À SUBSTITUTION EN POSITIONS 7, 8 ET 10 UTILISÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE L'ADÉNOSINE, COMPOSITIONS PHARMACEUTIQUES ET LEUR UTILISATION
  申请人：MERCK SHARP & DOHME

  公开号：WO2020112706A1

  公开（公告）日：2020-06-04

  In its many embodiments, the present invention provides certain 7-, 8-, and 10-substituted amino triazolo quinazoline derivatives of Formula (I): or a pharmaceutically acceptable salt thereof, wherein ring A, R1, R2, and R4 are as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutic agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

  在其多种实施方式中，本发明提供了某些7-、8-和10-取代氨基三唑喹唑啉衍生物的化合物（I）的制备方法和用途，或其药学上可接受的盐，其中环A、R1、R2和R4如本文所定义，包括一种或多种这样的化合物的药物组合物（单独使用和与一种或多种其他治疗剂联合使用），以及其制备和用途的方法，单独使用和与其他治疗剂联合使用，作为A2a和/或A2b受体的拮抗剂，并且它们在治疗由腺苷A2a受体和/或腺苷A2b受体至少部分介导的各种疾病、症状或紊乱中的用途。
• [EN] GLYCINE METABOLISM MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DU MÉTABOLISME DE LA GLYCINE ET LEURS UTILISATIONS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2018021977A1

  公开（公告）日：2018-02-01

  The present invention relates to a compound of general formula (I) and/or its solvates, hydrates and pharmaceutically acceptable salts, which are modulators of glycine metabolism. The present invention also relates to the methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of disorders/conditions/diseases involving, relating to or associated with glycine metabolism or a pathway where glycine decarboxylase (GLDC, or glycine cleavage system) plays a role. In a preferred embodiment the disorders/conditions/disease is cancer, inflammatory conditions, Alzheimer's disease, metabolic disorders and CNS disorders.

  本发明涉及一般式(I)的化合物及/或其溶剂合物、水合物和药学上可接受的盐，这些化合物是甘氨酸代谢调节剂。本发明还涉及其制备方法、含有这些化合物的药物组合物以及这些化合物在治疗涉及或与甘氨酸代谢或甘氨酸脱羧酶（GLDC，或甘氨酸裂解系统）发挥作用的病症/疾病/疾病的用途。在一个首选实施例中，疾病/疾病是癌症、炎症性疾病、阿尔茨海默病、代谢性疾病和中枢神经系统疾病。
• Chemical compounds
  申请人：Barton John Peter

  公开号：US20070112000A1

  公开（公告）日：2007-05-17

  The use of compounds of formula (I) wherein variable groups are defined within; in the manufacture of medicaments for use in the inhibition of 11βHSD1, process for making them, certain compounds within the definition of the formula (I) and pharmaceutical compositions comprising them are described. The compounds are useful in the treatment of metabolic syndrome, diabetes and obesity.

  本文描述了在制造用于抑制11βHSD1的药物时，使用式（I）中定义的可变基团的化合物，制造它们的过程，以及包含它们的某些化合物和药物组合物的定义。这些化合物对代谢综合征、糖尿病和肥胖症的治疗有用。
• PHOTOELECTRIC CONVERSION ELEMENT, SOLAR BATTERY, METHOD FOR MANUFACTURING PHOTOELECTRIC CONVERSION ELEMENT, AND SURFACE TREATMENT AGENT FOR PEROVSKITE-TYPE CRYSTAL FILM
  申请人：FUJIFILM Corporation

  公开号：EP3509117A1

  公开（公告）日：2019-07-10

  Provided is a photoelectric conversion element in which a photosensitive layer is composed of a light absorbing agent containing a perovskite compound, the element including a protective layer that includes a compound having a molecular weight of 5000 or less which is represented by Formula (A), on a surface of the photosensitive layer; a method for manufacturing this photoelectric conversion element; and a solar cell which is formed of this photoelectric conversion element.         Formula (A)     RA-Z In Formula (A), RA represents a specific group. Z represents an acidic group or a salt thereof. Further provided is a surface treating agent for a perovskite-type crystal film, including a compound having a molecular weight of 5000 or less which is represented by Formula (A).

  本发明提供了一种光电转换元件，其中的光敏层由含有过氧化物化合物的光吸收剂组成，该元件包括保护层，保护层包括在光敏层表面的分子量为 5000 或更小的由式（A）表示的化合物；一种制造这种光电转换元件的方法；以及一种由这种光电转换元件构成的太阳能电池。 式（A） RA-Z 式（A）中，RA 代表特定基团。Z 代表酸性基团或其盐。 本发明还提供一种包晶型晶体薄膜的表面处理剂，包括一种分子量在 5000 或以下、由式（A）表示的化合物。